Semnur Pharmaceuticals, Denali Capital Acquisition Sign LoI For Proposed Business Combination, Which Provides For Pre-Transaction Equity Value Of Semnur Of Up To $2.0B
Author: Benzinga Newsdesk | July 02, 2024 05:18pm
Scilex is expected to be the majority holder of the combined company following completion of the proposed business combination.